Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (386)	11/17/1998 10:16:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

I just got confirmation from NTII that the Phase II memantine trial for AIDS Dementia is designed to be pivotal. If the results are good, and all indications are that things are going well, then the intent is to submit an NDA to the FDA using the Phase II results. They've got plenty of safety data from Merz, there is nothing else to treat AIDS Dementia, its a growing problem, the AIDS community is on board and enthusiastic, ergo, if the results are good, it should be a shoe in for approval. John de C